XML 44 R32.htm IDEA: XBRL DOCUMENT

Debt - (Tables)

9 Months Ended

Sep. 30, 2025

Debt Instrument, Redemption [Line Items]

Summary of liability for sale of future royalties


		Nine Months Ended September 30,
Liability for sale of future royalties- (current and noncurrent)		2025
Beginning balance as of December 31, 2024		$	2,081,776
Less: Non-cash royalty revenue payable to Royalty Pharma			(149,160)
Plus: Non-cash interest expense recognized			149,305
Ending balance		$	2,081,921
Effective interest rate as of September 30, 2025			9.3%

2026 Convertible Notes

Debt Instrument, Redemption [Line Items]

Summary of convertible notes



		September 30, 2025			December 31, 2024
Principal		$	287,500		$	287,500
Less: Debt issuance costs			(1,181)			(2,088)
Net carrying amount		$	286,319		$	285,412

Summary of interest expense recognized related to the Convertible Notes


			Three Months Ended September 30,						Nine Months Ended September 30,
		2025			2024			2025			2024
Contractual interest expense		$	1,081		$	1,081		$	3,217		$	3,224
Amortization of debt issuance costs			306			300			906			891
Total		$	1,387		$	1,381		$	4,123		$	4,115
Effective interest rate			1.9	%		1.9	%		1.9	%		1.9	%